Implementing a PCNE-DRPs-Based Pharmaceutical Care Model for Hyperuricemia Management: Protocol Design and Real-World Application

INTERVENTION: Experimental group:Pharmacists provided a 12‐month follow‐up of compliance with urate‐lowering therapy. Follow‐up content: 1. Monitor patient medication adherence, adverse drug reactions, number of acute gout attacks, and blood uric acid levels; 2. Intervene and document any existing or newly occurring drug‐related problems (DRPs); 3. Address patients' questions related to medication use; 4. Advise patients to seek timely medical attention for issues that cannot be managed locally, such as severe adverse drug reactions, inadequate therapeutic response, or disease recurrence;Control group:Routine care management; CONDITION: Hyperuricemia PRIMARY OUTCOME: Occurrences of acute gout flare;Uric acid levels;Serum creatinine levels; SECONDARY OUTCOME: Disease awareness and medication adherence;The incidence of Drug relatived Problems; INCLUSION CRITERIA: 1. Aged 18 to 80 years; 2. Diagnosed with hyperuricemia according to the Chinese Guidelines for the Diagnosis and Management of Hyperuricemia and Gout (2019), defined as fasting serum uric acid (SUA) levels exceeding 420 µmol/L on two separate occasions under normal dietary conditions, regardless of gender; 3. Provided written informed consent.